Harold Aubrey de Lavenu - 12 Jul 2017 Form 3/A - Amendment Insider Report for CEN BIOTECH INC (CENBF)

Role: Director
Signature: /s/ Harold Aubrey de Lavenu
Issuer symbol: CENBF
Transactions as of: 12 Jul 2017
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 28 May 2021, 08:30:22 UTC
Date Of Original Report: 22 Apr 2021
Next filing: 28 May 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CENBF	Common Stock						13,321	12 Jul 2017	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CENBF	Convertible Note							12 Jul 2017	Common Stock	62,500	$1.60	Direct	F2, F3
holding	CENBF	Convertible Note							12 Jul 2017	Common Stock	125,000	$1.60	Direct	F2, F3
holding	CENBF	Convertible Note							12 Jul 2017	Common Stock	156,250	$1.60	Direct	F2, F3
holding	CENBF	Convertible Note							12 Jul 2017	Common Stock	312,500	$1.60	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Harold Aubrey de Lavenu (the "Reporting Person") was appointed to his position with CEN Biotech, Inc. (the "Issuer") on July 12, 2017 and owned 13,321 shares of the Issuer's common stock on such date. On April 2, 2021, the Issuer appointed the Reporting Person to serve as a Vice President of the Issuer effective as of April 2, 2021
F2	Additionally the Reporting Person owned convertible notes on July 12, 2017, which the Reporting Person purchased from the Issuer which were at such time and still are convertible into 656,250 shares of the Issuer's common stock.
F3	The convertible notes included in this table matured on May 12, 2018, November 25, 2018, December 14, 2018, and February 19, 2019, respectively, (the "Maturity Dates"), however, the ability to convert the notes into shares did not expire on the Maturity Dates of the notes.